Table 1.
Clinical characteristics of the 112 endometrioid ovarian carcinoma cases.
| N/median | %/range | |
|---|---|---|
| Cases | 112 | |
| Age (years) | 58.5 | 28–88 |
| BMI (kg per square metre height) | 25.4 | 18.0–44.0 |
| Concurrent endometrial cancera | 19 | 17.0 |
| Endometrioisisb | 39 | 34.8 |
| Grade | ||
| Grade 1 EnOC | 69 | 61.6 |
| Grade 2 EnOC | 17 | 15.2 |
| Grade 3 EnOC | 8 | 7.1 |
| Undifferentiated | 3 | 2.7 |
| Serous-like features | 15 | 13.4 |
| Vital status at last follow-up | ||
| Deceased, ovarian cancer | 35 | 31.3 |
| Deceased, other causes | 19 | 17.0 |
| Alive | 58 | 51.8 |
| Period of diagnosis | ||
| 1980s | 17 | 15.2 |
| 1990s | 44 | 39.3 |
| 2000s | 32 | 28.6 |
| 2010s | 19 | 17.0 |
| FIGO stage at diagnosis | ||
| I | 47 | 42.7 |
| II | 39 | 35.5 |
| III | 15 | 13.6 |
| IV | 9 | 8.2 |
| NA | 2 | – |
| Primary debulking status | ||
| Zero macroscopic RD | 82 | 78.1 |
| Macroscopic RD | 23 | 21.9 |
| NA | 7 | – |
| Adjuvant chemotherapy stage I/II (n = 86) | ||
| Single-agent platinum | 31 | 36.5 |
| Platinum–taxane combination | 17 | 20.0 |
| Other platinum combination | 3 | 3.5 |
| Other chemotherapy regime | 7 | 8.2 |
| No adjuvant chemotherapy | 27 | 31.8 |
| NA | 1 | – |
| Adjuvant therapy stage III/IV (n = 24) | ||
| Single-agent platinum | 14 | 58.3 |
| Platinum–taxane combination | 2 | 8.3 |
| Other platinum combination | 2 | 8.3 |
| Other chemotherapy regime | 1 | 4.2 |
| No adjuvant chemotherapy | 5 | 20.8 |
BMI body mass index, EnOC endometrioid ovarian carcinoma, NA not available, RD residual disease, FIGO International Federation of Obstetrics and Gynecology.
aDocumented on the Edinburgh Ovarian Cancer Database.
bDocumented on the diagnostic pathology report or identified from reviewed archival tissue.